1. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study;Burger;Leukemia,2020
2. Chronic lymphocytic leukemia: real-world data from India;Tejaswi;JCO Glob Oncol,2020
3. Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia;Hegde;Ann Hematol,2023
4. Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India;Nehra;Lancet Reg Health Southeast East Asia,2023
5. Development of the Indian Reference Case for undertaking economic evaluation for health technology assessment;Sharma;Lancet Reg Health Southeast East Asia,2023